Ignite Creation Date:
2024-05-06 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 2:24 PM
Study NCT ID:
NCT05231122
Status:
RECRUITING
Last Update Posted:
2024-03-27
First Post:
2022-01-24
Brief Title:
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Sponsor:
Roswell Park Cancer Institute
Organization:
Roswell Park Cancer Institute
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-03-12
Start Date Type:
ACTUAL
Primary Completion Date:
2026-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-12-30
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-24
First Submit QC Date:
January 28 2022
Study First Post Date:
2022-02-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-10-02
Last Update Post Date:
2024-03-27
Last Update Post Date Type:
ACTUAL